Ulteriori informazioni
Offers critical reviews of important topics in medicinal chemistry together with an emphasis on topics in the biological sciences, which provide the basis for various therapies. This title covers findings related to cardiovascular, inflammation, and pulmonary diseases. It examines issues in oncology, from mTor inhibitors to drug targets.
Sommario
Section I: Central Nervous System Diseases - ROBICHAUD
- Voltage-Gated Calcium Channel Antagonists for the Central Nervous System
James C. Barrow and Joseph L. Duffy
- Recent Developments in Glycine Transporter-1 Inhibitors
Christopher L. Cioffi, Shuang Liu and Mark A.Wolf
- Modulators of Transient Receptor Potential Ion Channels
Rajagopal Bakthavatchalam and S. David Kimball
- Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-species Pharmacologic Exposure-Response Relationships
Christopher L. Shaffer
Section II: Cardiovascular and Metabolic Diseases - STAMFORD
- High Affinity Niacin Receptor GPR109A Agonists
Hong C. Shen and Steven L. Colletti
- Recent Advances in Acetyl CoA Carboxylase (ACC) Inhibitors
Matthew P. Bourbeau, John G. Allen, and Wei Gu
- Enzymatic Targets in the Triglyceride Synthesis Pathway
Dmitry O. Koltun and Jeff Zablocki
- Inhibitors of HIF Prolyl Hydroxylases
Michael H. Rabinowitz, Terrance D. Barrett, Mark D. Rosen, Hariharan Venkatesan
Section III: Inflammation / Pulmonary / GI - BARRISH/Weinstein
- Opioid Receptor Antagonists for Gastrointestinal Dysfunction
R. William Hipkin and Roland E. Dolle
- CFTR Modulators for the Treatment of Cystic Fibrosis
Sabine Hadida, Frederick Van Goor and Peter D. J. Grootenhuis
- Targeting B-cells in inflammatory disease
Kevin S. Currie
- Modulators of Toll-Like Receptor (TLR) Signaling
Mark Spyvee, Lynn Hawkins, and Sally Ishizaka
Section IV: Oncology - McAlpine
- Janus Kinase 2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasm (MPN)
Ashok V. Purandare, Matthew V. Lorenzi and Louis J. Lombardo
- Development of poly(ADP-ribose)polymerase (PARP) inhibitors in oncology
Philip Jones
- Epigenetic Targets and Cancer Drug Discovery
Patrick M. Woster, Ph.D
Section V: Infectious Diseases - Primeau
- HIV-1 Integrase Strand Transfer Inhibitors
Brian A. Johns
- Recent Advances in Drug Discovery for Neglected Tropical Diseases Caused by Infective Kinetoplastid Parasites
Robert T. Jacobs and Charles Ding
- Recent Advances in the Inhibition of Bacterial Fatty Acid Biosynthesis
Vincent Gerusz
Section VI: Topics in Biology - LOWE
- Back to the Plaque: Emerging Studies That Re-Focus Attention on the Neuritic Plaque in Alzheimer's Disease
Dr. Robert B. Nelson
- Targeting Methyl Lysine
Stephen V. Frye, Tom Heightman and Jian Jin
- Chemical Proteomic Technologies for Drug Target Identification
Kieran F. Geoghegan and Douglas S. Johnson
- NIH Translational Programs for Assisting Pre-Clinical Drug Discovery and Development
Raj N. Misra
Section VII: Topics in Drug Design and Discovery - DESAI
- Role of Physicochemical Properties and Lipophilic Ligand Efficiency (LipE or LLE) in addressing Drug Safety Risks
Martin P. Edwards and David A. Price
- Reducing the Risk of Drug Attrition Associated with Physicochemical Properties
Paul D. Leeson and James R. Empfield
- Compound Collection Enhancement and Paradigms for High Throughput Screening - an Update
Stevan W Djuric, Irini Akritopoulou-Zanze, Philip B Cox and Scott Galasinski
- The Role of Fluorine in the Discovery and Optimization of CNS Agents: Modulation of Drug-Like Properties
Kevin J. Hodgetts, Kerry J. Combs, Amy M. Elder and Geraldine C. Harriman
- Patents in Drug Discovery: Case Studies, Examples, and Simple Steps Medicinal Chemists Can Take to Protect Hard-Won Intellectual Property
Charles J. Andres, Jr. and Richard L. Treanor
Section VIII: Trends and Pers
